April 16, 2026
[Co-founder first name],
Thanks for the time yesterday. The 90-95% NPS you mentioned stuck with me. In healthcare tech, scores that high mean the product works, not just gets tolerated. That's rare.
When you asked about Claude-generated code review discipline, I went to the failure mode I've seen elsewhere. Should have led with this: I'm building with Claude Code every day as my primary engineering tool right now. Not evaluating it. Shipping production features, architecture decisions, review discipline baked into the workflow. That's the muscle I'd bring on day one.
Also worth saying plainly. I mentioned rail billing and dementia detection as things I've been exploring. To be clearer: Dimer is the role I'd choose. Post-discharge care, Claude Code in the stack, Series A, hybrid team with senior Polish engineers I'd partner with rather than replace. This is the exact profile I'd build if I were starting over.
One more thing on scale I didn't land in the conversation. The platform I built at Credentia is still running today. Over a million certifications across 35 states, bootstrapped, profitable from year one, no outside capital. Happy to connect you with three people who saw me operate across a full product cycle: a co-founder, an operations lead, and a board member. Let me know if useful and I'll make the introductions.
Kevin